Evidence map›Paper›PMID 39852047›Full record

ReviewGels (Basel, Switzerland)2025

Recent Advances in Metal-Organic Framework-Based Anticancer Hydrogels.

Preeti Kush, Ranjit Singh, Parveen Kumar

Abstract readReview
In one paragraph

Review in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Preeti KushAdarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit University Gangoh, Saharanpur 247341, Uttar Pradesh, India.
Ranjit SinghAdarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit University Gangoh, Saharanpur 247341, Uttar Pradesh, India.
Parveen KumarExigo Recycling Pvt Ltd., Karnal 132114, Haryana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is the second leading cause of death globally and the estimated number of new cancer cases and deaths will be ∼30.2 million and 16.3 million, respectively, by 2040. These numbers cause massive, physical, emotional, and financial burdens to society and the healthcare system that lead to further research for a better and more effective therapeutic strategy to manage cancer. Metal-organic frameworks (MOFs) are promising alternative approaches for efficient drug delivery and cancer theranostics owing to their unique properties and the direct transportation of drugs into cells followed by controlled release, but they suffer from certain limitations like rigidity, poor dispersibility, fragility, aggregation probability, and limited surface accessibility. Therefore, MOFs were conjugated with polymeric hydrogels, leading to the formation of MOF-based hydrogels with abundant absorption sites, flexibility, and excellent mechanical properties. This review briefly describes the different strategies used for the synthesis and characterization of MOF-based hydrogels. Further, we place special emphasis on the recent advances in MOF-based hydrogels used to manage different cancers. Finally, we conclude the challenges and future perspectives of MOF-based hydrogels. We believe that this review will help researchers to develop more MOF-based hydrogels with augmented anticancer effects, enabling the effective management of cancer even without adverse effects.

Indexed as

challengeschemotherapyhydrogelmetal–organic framework

Identifiers

PMID39852047
PMCPMC11764634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.